FINWIRES · TerminalLIVE
FINWIRES

Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating

By

Alnylam Pharmaceuticals (ALNY) has an average rating of overweight and mean price target of $444.35, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Price: $338.14, Change: $+14.64, Percent Change: +4.52%

Related Articles